London Co. of Virginia Has $22 Million Holdings in Haemonetics Co. (NYSE:HAE)

London Co. of Virginia raised its position in Haemonetics Co. (NYSE:HAE) by 2.2% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 281,738 shares of the medical instruments supplier’s stock after buying an additional 6,111 shares during the quarter. London Co. of Virginia owned about 0.56% of Haemonetics worth $21,998,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in HAE. TD Waterhouse Canada Inc. acquired a new stake in shares of Haemonetics in the 4th quarter valued at approximately $25,000. Covestor Ltd increased its holdings in shares of Haemonetics by 146.8% during the fourth quarter. Covestor Ltd now owns 738 shares of the medical instruments supplier’s stock worth $58,000 after buying an additional 439 shares in the last quarter. Whittier Trust Co. bought a new stake in Haemonetics during the 4th quarter worth $62,000. Parkside Financial Bank & Trust increased its holdings in Haemonetics by 25.6% in the 4th quarter. Parkside Financial Bank & Trust now owns 1,176 shares of the medical instruments supplier’s stock worth $92,000 after purchasing an additional 240 shares in the last quarter. Finally, AlphaQuest LLC raised its position in Haemonetics by 36,520.0% in the fourth quarter. AlphaQuest LLC now owns 1,831 shares of the medical instruments supplier’s stock valued at $143,000 after purchasing an additional 1,826 shares during the last quarter. 99.67% of the stock is owned by institutional investors.

Haemonetics Stock Up 0.3%

HAE stock opened at $68.21 on Monday. Haemonetics Co. has a twelve month low of $55.30 and a twelve month high of $97.97. The business has a 50 day moving average of $62.75 and a 200 day moving average of $71.36. The firm has a market cap of $3.43 billion, a PE ratio of 26.85, a price-to-earnings-growth ratio of 1.11 and a beta of 0.32. The company has a quick ratio of 2.55, a current ratio of 3.97 and a debt-to-equity ratio of 1.35.

Haemonetics (NYSE:HAE) last posted its earnings results on Thursday, May 8th. The medical instruments supplier reported $1.24 earnings per share for the quarter, beating analysts’ consensus estimates of $1.22 by $0.02. Haemonetics had a return on equity of 23.66% and a net margin of 9.47%. The company had revenue of $330.60 million for the quarter, compared to the consensus estimate of $329.38 million. During the same quarter in the prior year, the company earned $0.90 earnings per share. Haemonetics’s revenue was down 3.5% on a year-over-year basis. On average, research analysts forecast that Haemonetics Co. will post 4.55 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

HAE has been the subject of several analyst reports. Needham & Company LLC dropped their price target on shares of Haemonetics from $104.00 to $84.00 and set a “buy” rating for the company in a research note on Thursday. Barrington Research dropped their price target on Haemonetics from $108.00 to $95.00 and set an “outperform” rating on the stock in a research note on Friday, February 7th. Bank of America lowered shares of Haemonetics from a “neutral” rating to an “underperform” rating and decreased their price target for the stock from $95.00 to $68.00 in a research note on Friday, February 7th. JMP Securities reduced their target price on shares of Haemonetics from $125.00 to $100.00 and set a “market outperform” rating for the company in a research note on Friday, February 7th. Finally, Raymond James reiterated a “strong-buy” rating and issued a $105.00 price objective (down previously from $115.00) on shares of Haemonetics in a research report on Friday. One research analyst has rated the stock with a sell rating, one has issued a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $97.89.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.